Activity of protein phosphatase calcineurin is decreased in sporadic and familial amyotrophic lateral sclerosis patients

Journal of Neurochemistry

Volumn 90, Issue 5, 2004, Pages 1237-1242

  Ferri, Alberto ^a,b   Nencini, Monica ^b   Battistini, Stefania ^c   Giannini, Fabio ^c   Siciliano, Gabriele ^d   Casali, Carlo ^e   Damiano, Maria G ^e,f   Ceroni, Mauro ^g,h   Chiò, Adriano ⁱ   Rotilio, Giuseppe ^j   Carrì, Maria Teresa ^j  

^a CNR   (Italy)

^b Reparto Medicina Aeronautica e Spaziale   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF PAVIA   (Italy)

^h Polyclinic of Monza ^*  (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j UNIVERSITY OF ROME TOR VERGATA   (Italy)

more..

Author keywords

Amyotrophic lateral sclerosis; Calcineurin; Reactive oxygen species; Superoxide dimutase

Indexed keywords

CALCINEURIN; PHOSPHOPROTEIN PHOSPHATASE; REACTIVE OXYGEN METABOLITE; RILUZOLE; SUPEROXIDE DISMUTASE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FAMILIAL DISEASE; GENE MUTATION; HUMAN; HUMAN CELL; LYMPHOCYTE; MOTOR NEURON DISEASE; OXIDATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TREATMENT OUTCOME; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; BLOTTING, WESTERN; CALCINEURIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NUCLEAR PORE COMPLEX PROTEINS; RILUZOLE; SUPEROXIDE DISMUTASE;

MUS MUSCULUS;

EID: 4444383980     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02588.x     Document Type: Article

References (42)

1. Beal M. F. (2000) Mitochondria and the pathogenesis of ALS. Brain. 123, 1291-1292.
2. Bechstein W. O. (2000) Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl. Int. 13, 313-326.
3. Bogdanov M., Brown H. R. Jr, Matson W., Smart R., Hayden D., O'Donnell H., Beal M. F. and Cudkowicz M. (2000) Increased oxidative damage to DNA in ALS patients. Free Radic. Biol. Med. 29, 652-658.
4. Bonnefont-Rousselot D., Lacomblez L., Jaudon M., Lepage S., Salachas F., Bensimon G., Bizard C., Doppler V., Delattre J. and Meininger V. (2000) Blood oxidative stress in amyotrophic lateral sclerosis. J. Neurol. Sci. 178, 57-62.
5. Carballo M., Marquez G., Conde M., Martin-Nieto J., Monteseirin J., Conde J., Pintado E. and Sobrino F. (1999) Characterization of calcineurin in human neutrophils. Inhibitory effect of hydrogen peroxide on its enzyme activity and on NF-kappaB DNA binding. J. Biol. Chem. 274, 93-100.
6. 2+ concentration in transfected neuroblastoma SH-SY5Y cells. FEBS Lett. 414, 365-368.
7. Carrì M. T., Ferri A., Cozzolino M., Calabrese L. and Rotilio G. (2003) Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res. Bull. 61, 365-374.
8. Carter G. T., Krivickas L. S., Weydt P., Weiss M. D. and Miller R. G. (2003) Drug therapy for amyotrophic lateral sclerosis: Where are we now? Idrugs 6, 147-153.
9. Casciati A., Ferri A., Cozzolino M., Celsi F., Nencini M., Rotilio G. and Carrì M. T. (2002) Oxidative modulation of NF-κB in human cells expressing mutant FALS-typical superoxide dismutases. J. Neurochem. 83, 1019-1029.
10. Curti D., Malaspina A., Facchetti G., Camana C., Mazzini L., Tosca P., Zerbi F. and Ceroni M. (1996) Amyotrophic lateral sclerosis: oxidative energy metabolism and calcium homeostasis in peripheral blood lymphocytes. Neurology 47, 1060-1064.
11. Dawson T. M., Steiner J. P., Dawson V. L., Dinerman J. L., Uhl G. R. and Snyder S. H. (1993) Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc. Natl. Acad. Sci. USA 90, 9808-9812.
12. Dumont F. J. (2000) FK506, an immunosuppressant targeting calcineurin function. Curr. Med. 7, 731-748.
13. Ferrante R. J., Browne S. E., Shinobu L. A., Bowling A. C., Baik M. J., MacGarvey U., Kowall N. W., Brown R. H. Jr and Beal M. F. (1997) Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 69, 2064-2074.
14. Ferri A., Gabbianelli R., Casciati A., Paolucci E., Rotilio G. and Carrì M. T. (2000) Calcineurin activity is regulated both by redox compounds and by mutant familial amyotrophic lateral sclerosis-superoxide dismutase. J. Neurochem. 75, 606-613.
15. Ferri A., Casciati A., Celsi F., Rotilio G. and Carrì M. T. (2001) Oxidative inactivation of calcineurin by Cu,Zn superoxide dismutase G93A, a mutant typical of familial amyotrophic lateral sclerosis. J. Neurochem. 79, 531-538.
16. Hu J. H., Chernoff K., Pelech S. and Krieger C. (2003a) Protein kinase and protein phosphatase expression in the central nervous system of G93A mSOD over-expressing mice. J. Neurochem. 85, 422-431.
17. Hu J. H., Zhang H., Wagey R., Krieger C. and Pelech S. L. (2003b) Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. J. Neurochem. 85, 432-442.
18. Ingebritsen T. S. and Cohen P. (1983) Protein phosphatases: properties and role in cellular regulation. Science 221, 331-337.
19. Koh J. Y., Kim D. K., Hwang J. Y., Kim Y. H. and Seo J. H. (1999) Antioxidative and proapoptotic effects of riluzole on cultured cortical neurons. J. Neurochem. 72, 716-723.
20. Ladner C. J., Czech J., Maurice J., Lorens S. A. and Lee J. M. (1996) Reduction of calcineurin enzymatic activity in Alzheimer's disease: correlation with neuropathologic changes. J. Neuropathol. Exp. Neurol. 55, 924-931.
21. Laemmli U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
22. 2+-dependent phosphatase. Nature 369, 235-239.
23. Louvel E., Hugon J. and Doble A. (1997) Therapeutic advances in amyotrophic lateral sclerosis. Trends Pharmacol. Sci. 18, 196-203.
24. Lukyanetz E. A. (1997) Evidence for colocalization of calcineurin and calcium channels in dorsal root ganglion neurons. Neurosci. 78, 625-628.
25. Morioka M., Hamada J.-I., Ushio Y. and Miyamoto E. (1999) Potential role of calcineurin for brain ischemia and traumatic injury. Prog. Neurobiol. 58, 1-30.
26. Nagano S., Fujii Y., Yamamoto T., Taniyama M., Fukada K., Yanagihara T. and Sakoda S. (2003) The efficacy of trientine or ascorbate alone compared to that of the combined treatment with these two agents in familial amyotrophic lateral sclerosis model mice. Exp Neurol. 179, 176-180.
27. Namgaladze D., Hofer H. W. and Ullrich V. (2002) Redox control of calcineurin by targeting the binuclear Fe (2+)-Zn (2+) center at the enzyme active site. J. Biol. Chem. 277, 5962-5969.
28. Nicols R. A., Suplick G. R. and Brown J. M. (1994) Calcineurin-mediated protein dephosphorylation in brain nerve terminals regulates the release of glutamate. J. Biol. Chem. 269, 23817-23823.
29. Quinland E. M. and Halpain S. (1996) Postsynaptic mechanisms for bidirectional control of MAP2 phosphorylation by gluthamate receptors. Neuron 16, 357-368.
30. Reinholz M. M., Merkle C. M. and Poduslo J. F. (1999) Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis. Exp Neurol. 159, 204-216.
31. Reuter A., Mi J., Sehrsam I., Ludolph A. C. and Volkel H. (2001) A novel calcineurin splice variant that modifies calcineurin activity. Eur. J. Biochem. 268, 5955-5960.
32. Rusnak F. and Mertz P. (2000) Calcineurin: form and function. Physiol. Rev. 80, 1483-1521.
33. 2+-activated cell death in mammalian cells. J. Cell Biol. 131, 735-743.
34. Siklos L., Engelhardt J. I., Adalbert R. and Appel S. H. (1999) Calcium-containing endosomes at oculomotor terminals in animal models of ALS. Neuroreport. 10, 2539-2545.
35. Storch A., Burkhardt K., Ludolph A. C. and Schwarz J. (2000) Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J. Neurochem. 75, 2259-2269.
36. Tong G., Shepherd D. and Jahr C. E. (1995) Synaptic desensitization of NMDA receptors by calcineurin. Science 267, 1510-1512.
37. Valentine J. S. (2002) Do oxidatively modified proteins cause ALS? Free Radic. Biol. Med. 33, 1314-1320.
38. Volkel H., Scholz M., Link J., Selzle M., Werner P., Tunnemann R., Jung G., Ludolph A. C. and Reuter A. (2001) Superoxide dismutase mutations of familial amyotrophic lateral sclerosis and the oxidative inactivation of calcineurin. FEBS Lett. 503, 201-205.
39. Wang X., Culotta V. C. and Klee C. B. (1996) Superoxide dismutase protects calcineurin from inactivation. Nature 383, 434-437.
40. Wang H. G., Pathan N., Ethell I. M., Krajewski S., Yamaguchi Y., Shibasaki F., McKeon F., Bobo T., Franke T. F. and Reed J. C. (1999) Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 284, 339-343.
41. Yakel J. L. (1997) Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene transcription. Trends Pharmacol. Sci. 18, 124-134.
42. Zhu Y. and Yakel J. L. (1997) Calcineurin modulates G protein-mediated inhibition of N-type calcium channels in rat sympthatetic neurons. J. Neurophisiol. 78, 1161-1165.